Published in Am J Hematol on January 01, 1998
Mast cells and mastocytosis. Blood (2008) 2.32
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol (2014) 1.14
Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc (2005) 0.81
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica (2013) 0.77
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis (1999) 2.28
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma (2007) 2.21
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant (2008) 2.10
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant (2013) 2.04
Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2001) 2.00
Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol (2001) 1.83
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol (2001) 1.76
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (1987) 1.76
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol (2005) 1.65
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant (2000) 1.62
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene (2001) 1.58
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood (1999) 1.58
Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis (2001) 1.57
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood (1995) 1.45
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol (2000) 1.40
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion (1996) 1.40
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant (2005) 1.39
Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol (2001) 1.39
Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant (2008) 1.36
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol (2000) 1.36
Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood (1996) 1.33
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood (2000) 1.33
Ex vivo expansion of umbilical cord blood. Cytotherapy (2005) 1.32
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood (2001) 1.32
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia (2009) 1.28
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant (2001) 1.27
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant (2009) 1.27
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood (2000) 1.26
Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant (2011) 1.26
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia (2013) 1.26
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant (2006) 1.23
Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis (1996) 1.20
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia (2007) 1.20
Non-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program (2001) 1.20
CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant (2009) 1.19
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology (2010) 1.18
Toll-like receptor alterations in myelodysplastic syndrome. Leukemia (2013) 1.16
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology (2007) 1.14
Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park) (1999) 1.13
Acute myelogenous leukemia: recent advances in therapy. Blood (1987) 1.11
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant (1999) 1.11
Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion (1997) 1.09
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood (1996) 1.08
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant (2005) 1.07
Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy (2006) 1.06
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant (2009) 1.06
Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet (1984) 1.06
Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant (1999) 1.06
Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood (2000) 1.06
Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med (1983) 1.06
Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant (2000) 1.05
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol (1992) 1.04
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant (2006) 1.03
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood (1995) 1.03
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood (1992) 1.03
Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant (2003) 1.02
Mini-allografts: ongoing trials in humans. Bone Marrow Transplant (2000) 1.02
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol (1998) 1.02